Author details

Full Name

Yiling Lu

Affiliation

ORCID

Career Start Year

1990

Papers

224

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
35138907	A functional genomic approach to actionable gene fusions for precision oncology.	Sci Adv	2022
36247238	Long noncoding RNA urothelial carcinoma associated 1 protects human placental vascular endothelial cells from hypoxia-induced damage by regulating the miR-197-3p/histone deacetylase-2 axis in patients with pregnancy-induced hypertension.	American Journal of Translational Research (discontinued)	2022
36309506	Proteo-genomic characterization of virus-associated liver cancers reveals potential subtypes and therapeutic targets.	Nat Commun	2022
35810190	Multi-modal molecular programs regulate melanoma cell state.	Nat Commun	2022
35687899	Hsa_circ_0063804 enhances ovarian cancer cells proliferation and resistance to cisplatin by targeting miR-1276/CLU axis.	Aging	2022
36207580	A multi-omic analysis of MCF10A cells provides a resource for integrative assessment of ligand-mediated molecular and phenotypic responses.	Commun Biol	2022
35736816	Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary BRCA Mutation.	Clinical Cancer Research	2022
36332624	Tumor-intrinsic SIRPA promotes sensitivity to checkpoint inhibition immunotherapy in melanoma.	Cancer Cell	2022
36205581	RPPA SPACE: an R package for normalization and quantitation of Reverse-Phase Protein Array data.	Bioinformatics	2022
35538088	Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naÃ¯ve gBRCA+ breast cancers.	NPJ Breast Cancer	2022
36448064	Aquaporin-8 overexpression is involved in vascular structure and function changes in placentas of gestational diabetes mellitus patients.	Open Life Sciences	2022
35718998	Identification of potential gene markers in gestational diabetes mellitus.	Journal of Clinical Laboratory Analysis	2022
36516775	AKTIP loss is enriched in ERÎ±-positive breast cancer for tumorigenesis and confers endocrine resistance.		2022
35247901	Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas.	Clin Cancer Res	2022
34825915	WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway.	J Exp Med	2022
35002309	Development of Potential Prognostic Biomarkers Based on DNA Methylation-Driven Genes for Patients with Endometrial Cancer.	International Journal of General Medicine	2021
33658639	Frequent post-operative monitoring of colorectal cancer using individualised ctDNA validated by multiregional molecular profiling.	Br J Cancer	2021
34304249	Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma.	Oncogene	2021
34462276	Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance.	Cancer Res	2021
34560251	TOP1 modulation during melanoma progression and in adaptative resistance to BRAF and MEK inhibitors.	Pharmacol Res	2021
34593527	A Modified Nucleoside 6-Thio-2'-Deoxyguanosine Exhibits Antitumor Activity in Gliomas.	Clin Cancer Res	2021
33157050	Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines.	Cancer Cell	2020
32265228	Verteporfin Inhibits PD-L1 through Autophagy and the STAT1-IRF1-TRIM28 Signaling Axis, Exerting Antitumor Efficacy.	Cancer Immunol Res	2020
32385243	p85Î² regulates autophagic degradation of AXL to activate oncogenic signaling.	Nat Commun	2020
31705064	MCP-1/CCR-2 axis in adipocytes and cancer cell respectively facilitates ovarian cancer peritoneal metastasis.	Oncogene	2020
32820016	Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma.	Clin Cancer Res	2020
33087324	Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling.	Cancer Res	2020
33027286	Analysis of mutational and proteomic heterogeneity of gastric cancer suggests an effective pipeline to monitor post-treatment tumor burden using circulating tumor DNA.	PLoS One	2020
31191824	Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options.	Oncotarget	2019
31598170	Impact of Cold Ischemic Time and Freeze-Thaw Cycles on RNA, DNA and Protein Quality in Colorectal Cancer Tissues Biobanking.	Journal of Cancer	2019
31682236	A-to-I-edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis.	J Clin Invest	2019
31875548	miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer.	Cell Rep	2019
31820388	Generation of Raw RPPA Data and Their Conversion to Analysis-Ready Data.	Adv Exp Med Biol	2019
31820387	Antibody Screening.	Adv Exp Med Biol	2019
31820386	Analytical Platforms 3: Processing Samples via the RPPA Pipeline to Generate Large-Scale Data for Clinical Studies.	Adv Exp Med Biol	2019
30532003	Author Correction: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.	Nature	2019
31185210	Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy.	Cancer Cell	2019
30755611	Deregulated Gab2 phosphorylation mediates aberrant AKT and STAT3 signaling upon PIK3R1 loss in ovarian cancer.	Nat Commun	2019
31477280	Identification and validation of a prognostic proteomic signature for cervical cancer.	Gynecol Oncol	2019
30858377	Author Correction: Loss of Phd2 cooperates with BRAF<sup>V600E</sup> to drive melanomagenesis.	Nat Commun	2019
31433975	Suppression of p16 Induces mTORC1-Mediated Nucleotide Metabolic Reprogramming.	Cell Rep	2019
31068700	Next-generation characterization of the Cancer Cell Line Encyclopedia.	Nature	2019
31201206	TCPA v3.0: An Integrative Platform to Explore the Pan-Cancer Analysis of Functional Proteomic Data.	Mol Cell Proteomics	2019
31497537	CD44 Expression Predicts Prognosis of Ovarian Cancer Patients Through Promoting Epithelial-Mesenchymal Transition (EMT) by Regulating Snail, ZEB1, and Caveolin-1.	Frontiers in Oncology	2019
29725014	Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype.	Nat Commun	2018
30266942	Systems biology approach reveals a link between mTORC1 and G2/M DNA damage checkpoint recovery.	Nat Commun	2018
30012111	AKT isoform-specific expression and activation across cancer lineages.	BMC Cancer	2018
30096301	Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.	Cell	2018
30575721	Loss of Phd2 cooperates with BRAF<sup>V600E</sup> to drive melanomagenesis.	Nat Commun	2018
30089911	Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response.	Nature	2018